ISCO Signs Master Clinical Research Agreement with Duke University

The International Stem Cell Corporation (ISCO) has signed a master clinical research agreement with Duke University.

This involves the organisation performing clinical trials research in Parkinson’s disease using its neural stem cell product, with the university’s Clinical Research Institute coordinating the study.

Using novel therapeutic cellular product derived from the company’s proprietary histocompatible, human pluripotent stem cells, human parthenogenetic neural stem cells, the ISCO’s Parkinson’s disease programme will further investigate the causes and development of the condition.

Commenting on the partnership, Duke University School of Medicine neurology clinical research vice dean Mark Stacy said that the relationship could be very important to the current research surrounding Parkinson’s disease treatment.

He said: “Duke has an exceptional clinical trials team and we look forward to characterising and understanding the safety and efficacy profile of this agent in the clinical trials setting.”